Abstract
Introduction Immune checkpoint inhibitor (ICI) therapy is a major breakthrough in non-small cell lung cancer (NSCLC) treatment. However, valid predictive biomarkers are lacking. Blood cell count test (BCT) provides a direct quantification of various types of immune cells (ICs) to reveal the immune landscape to predict ICI treatment.
Methods This study analyzed four international, multi-center clinical trials (OAK, BIRCH, POPLAR and FIR trials) to conduct post-hoc analyses of NSCLC patients undergoing atezolizumab (anti-PD-L1) single-agent treatment (n = 1,479) or docetaxel single-agent treatment (n = 707). BCT was conducted at three timepoints: pre-treatment (T1), the first day of treatment cycle 3 (T2), and first day of treatment cycle 5 (T3). Univariate and multivariate Cox regression analyses were conducted to identify early BCT biomarkers to predict atezolizumab treatment outcomes in NSCLC patients.
Results The BCT biomarkers of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at timepoint T3 and neutrophil-to-monocyte ratio (NMR) at timepoint T2 were identified as strong predictive biomarkers for atezolizumab (Ate)-treated NSCLC patients in comparison to docetaxel (Dtx)-treated patients regarding overall survival (OS) (BCTscore low-risk: HR Ate vs Dtx = 1.54 (95% CI: 1.04-2.27), P = 0.036; high-risk: HR Ate vs Dtx = 0.84 (95% CI: 0.62-1.12), P = 0.236). This identified BCTscore model showed better OS AUC in the OAK (AUC12month=0.696), BIRCH (AUC12month=0.672) and POPLAR+FIR studies (AUC12month=0.727) than that of each of the three single BCT biomarkers.
Conclusion The BCTscore model is a valid predictive and prognostic biomarker for atezolizumab-treated NSCLC patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Pseudonymized individual participant data from the single-arm phase II studies FIR (NCT01846416) 19 and BIRCH (NCT02031458) 20, and the two-arm randomized controlled trials (RCTs) POPLAR phase II study (NCT01903993) 3 and OAK phase III study (NCT02008227) 4 were provided by Genentech Inc. and accessed through the secure Vivli online platform.
Funding Statement
This research was funded by the National Natural Science Foundation of China (Grant No. 81660512), the National Natural Science Foundation of Guizhou Province (Grant No. ZK2021-YB435), Research Programs of Science and Technology Commission Foundation of Zunyi City (Grant Nos. HZ2019-11, HZ2019-07), Research Programs of Health Commission Foundation of Guizhou Province (Grant Nos. gzwjkj2019-1-073, gzwjkj2019-1-172), Lian Yun Gang Shi Hui Lan Public Foundation (Grant No. HL-HS2020-92). AW Medical Company Limited received startup funding from the University Development Fund of University of Macau.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Secondary analysis of the trial data was deemed to be of negligible risk and was approved by the Institutional Review Board of the Second Affiliated Hospital, Zunyi Medical University (No.YXLL(KY-R)-2021-010).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-Mail of the authors: Dr. Jian-Guo Zhou: jianguo.zhou{at}fau.de
Dr. Ada Hang-Heng Wong: synxin2008{at}gmail.com
Dr. Haitao Wang: haitao.wang{at}nih.gov
Su-Han Jin: doctorjin1991{at}163.com
Fangya Tan: ftan1{at}my.harrsiburgu.edu
Yu-Zhong Chen : cyz19960118{at}gmail.com
Dr. Si-Si He: sisihe1219{at}163.com
Gang Shen: 280694526{at}qq.com
Dr. Benjamin Frey: Benjamin.Frey{at}uk-erlangen.de
Prof. Rainer Fietkau: Rainer.Fietkau{at}uk-erlangen.de
Dr. Markus Hecht: Markus.Hecht{at}uk-erlangen.de
Dr. Shamus R. Carr: shamus.carr{at}nih.gov
Dr. Ruihong Wang: ruihong.wang{at}nih.gov
Prof. Bo Shen: shenbo987{at}126.com
Prof. David S Schrump: David_Schrump{at}nih.gov
Prof. Hu Ma: mahuab{at}163.com
Prof. Udo S. Gaipl: udo.gaipl{at}uk-erlangen.de
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos